Abstract: Liquid drug preparations characterized by containing fudostein and an acid together with a sweetener such as sugar alcohol, trehalose or a sweetener having a high degree of sweetness. These liquid drug preparations are fudostein-containing liquid drug preparations which are free from color change or sedimentation upon prolonged storage and can be easily taken.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: Drug preparations characterized by containing fudosteine and an antitussive. These preparations are drugs to be used for common cold, etc. which have improved antitussive and sputum-removal effects.

Abstract: Liquid drug preparations characterized by containing fudostein and an acid together with a sweetener such as sugar alcohol, trehalose or a sweetener having a high degree of sweetness. These liquid drug preparations are fudostein-containing liquid drug preparations which are free from color change or sedimentation upon prolonged storage and can be easily taken.

Abstract: Medicinal compositions characterized by containing fudosteine and an antipyretic/analgesic. These medicinal compositions are medicinal compositions to be used for common cold, etc. which have improved sputum-removal and antiinflammatory effects.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: Provided is an aqueous gel preparation for covering wounds which contains a paste having a gel strength, in water, of 7.5 to 100 g. Such a wound covering preparation is effective for promoting wound healing, is capable of absorbing exudate sufficiently, does not adhere to the wound surface and can be held at the affected part stably.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

Abstract: An orally administrable uncompressed rapidly dissolving molded dosage form comprises a drug and either one or more saccharides or one saccharide and polyvinylpyrrolidone. Saccarides are chosen and used in proportion based on their solubilities. Methods for producing uncompressed rapidly dissolving solid preparations comprise mixing a drug and carriers according to the present invention and charging the mixture in a mold. Rapidly dissolving oral dosage forms facilitate administration of drugs to patients having a difficulty in swallowing such as children and the elderly.

Abstract: This invention relates to an intra-articular preparation for the treatment of arthropathy, which comprises microcapsules of (a) a high-molecular substance, which has biodegradability and biocompatibility, and (b) a drug. When applied directly to a joint area, this preparation can achieve a high drug concentration at the target area, can inhibit occurrence of general side effect, and can maintain drug efficacy over a long term. The preparation can therefore alleviate the burden on the patient.

Abstract: This invention relates to a drug composition with a controlled drug release rate. The drug composition comprises: a matrix formed of the following ingredients (a) and (b): (a) a biodegradable, biocompatible high-molecular substance and/or polyvalent metal ions or polyvalent metal ion source, and (b) hyaluronic acid or a salt thereof; and a drug incorporated as an ingredient (c) in said matrix. The drug composition has biodegradability and biocompatibility, permits easy control of a release rate of the drug, and can persistently exhibit its pharmacological effect over a long time.

Abstract: A hydrophilic adhesive mass contains 0.05 to 10 wt. % of a copolymer of an aminoalkyl (meth)acrylate and an alkyl (meth)acrylate. This hydrophilic adhesive mass is excellent in adhesiveness, and especially when combined with a pharmacologically active ingredient, is suitable for use in providing hydrophilic plasters.

Abstract: This invention relates to an intra-articular preparation for the treatment of arthropathy, which comprises microcapsules of (a) a high-molecular substance, which has biodegradability and biocompatibility, and (b) a drug. When applied directly to a joint area, this preparation can achieve a high drug concentration at the target area, can inhibit occurrence of general side effect, and can maintain drug efficacy over a long term. The preparation can therefore alleviate the burden on the patient.

Abstract: An antiinflammatory and analgesic gel preparation comprising diclofenac or its salts, an ester of dibasic acid, a lower alcohol, and a nonionic polymer or a mixture of nonionic polymers selected from the group consisting of (a) 1.5-4% by weight of hydroxypropyl cellulose having a molecular weight of 500,000 or greater, (b) 2-4% by weight of hydroxyethyl cellulose having a molecular weight of 1,250,000 or greater, and (c) 1.5-4% by weight of a mixture of hydroxypropyl cellulose having a molecular weight of 500,000 or greater and hydroxyethyl cellulose having a molecular weight of 1,250,000 or greater, and having a viscosity of 5,000-35,000 cps and an yield value of 5 dyn/cm.sup.2 or greater. The gel preparation is excellent in the percutaneous absorption of diclofenac or its salts and provides good properties upon use and superior medical effects of diclofenac or its salts.

Abstract: A pranoprofen-containing, suspending medicinal composition is formed of the following three ingredients (a) to (c):(a) pranoprofen;(b) a suspending agent comprising microcrystalline cellulose-sodium carboxymethylcellulose, sodium carboxymethylcellulose and hydroxypropyl methylcellulose; and(c) a saccharide solution.

Abstract: The present invention relates to an antiinflammatory gel preparation comprising an ammonium or sodium salt of diclofenac, a nonionic polymer, a dibasic ester, and a lower alcohol. The gel preparation of the present invention exhibits superior percutaneous absorptivity, thus providing sufficient medical effects of the two diclofenac salts. In addition, the preparation is stable over time even at a high concentration of the diclofenac salts.

Abstract: Described herein are antidiarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride.

Abstract: Described herein are antidirarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride.